The future of osteoporosis treatment – a research update

The future of osteoporosis treatment – a research update

Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture which leads to increased fracture risk. Some of the drugs available to date have shown reductions in vertebral and non-vertebral fracture risk. However, in the ageing population of industrialised count...

Full description

Bibliographic Details
Main Author:	Kurt Lippuner
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2012-07-01
Series:	Swiss Medical Weekly
Subjects:	bone formation bone resorption calcilytics cathepsin K denosumab dickkopf-1
Online Access:	https://www.smw.ch/index.php/smw/article/view/1528

Similar Items

Advances in the discovery of cathepsin K inhibitors on bone resorption
by: Jun Lu, et al.
Published: (2018-01-01)

Refractory hypercalcemia of malignancy: a problem with many potential roots
by: Azeez Farooki, et al.
Published: (2023-05-01)

Inhibitory Effects of 2N1HIA (2-(3-(2-Fluoro-4-Methoxyphenyl)-6-Oxo-1(6H)-Pyridazinyl)-<i>N</i>-1H-Indol-5-Ylacetamide) on Osteoclast Differentiation via Suppressing Cathepsin K Expression
by: Sun-Hee Ahn, et al.
Published: (2018-11-01)

THE ROLE OF CYTOKINE SYSTEM RANKL-RANK-OPG AND CATHEPSIN K IN THE PATHOGENESIS OF OSTEOPOROSIS: ACHIEVEMENTS AND PERSPECTIVES IN THE TREATMENT OF DISEASE
by: S. Sagalovsky, et al.
Published: (2015-10-01)

Cathepsin K: The Action in and Beyond Bone
by: Rongchen Dai, et al.
Published: (2020-06-01)

Bone turnover markers, use in osteoporosis
by: Astrid Kamilla Stunes, et al.
Published: (2013-05-01)

Emerging therapies for the treatment of osteoporosis
by: Garima Bhutani, et al.
Published: (2013-01-01)

Osteoclasts’ Ability to Generate Trenches Rather Than Pits Depends on High Levels of Active Cathepsin K and Efficient Clearance of Resorption Products
by: Xenia G. Borggaard, et al.
Published: (2020-08-01)

Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives
by: Tsung-Rong Kuo, et al.
Published: (2017-05-01)

Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis
by: Makoto Tanaka, et al.
Published: (2017-06-01)

Dickkopf-1 levels and serum Osteoprotegerin in women with Osteoporosis
by: Mehrzad Hajialilo, et al.
Published: (2013-12-01)

Research Progress of Ferroptosis Regulatory Network and Bone Remodeling in Osteoporosis
by: Chunlu Yan, et al.
Published: (2022-06-01)

BONE RESORPTION MARKER BETA-CROSSLAPS FOR EARLY MONITORING OF OSTEOPOROSIS TREATMENT WITH DENOSUMAB
by: Tatyana Simeonova, et al.
Published: (2022-12-01)

The Role of SIRT3 in the Osteoporosis
by: Siwang Hu, et al.
Published: (2022-05-01)

Microbial osteoporosis: The interplay between the gut microbiota and bones via host metabolism and immunity
by: Lishan Li, et al.
Published: (2019-08-01)

Osteoporosis pathogenesis and treatment: existing and emerging avenues
by: Bo Liang, et al.
Published: (2022-09-01)

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
by: Wei Lin Tay, et al.
Published: (2022-04-01)

The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis
by: S. Akı, et al.
Published: (2002-03-01)

Case of atypical femoral fractures that mimicked the typical imaging findings of prostate cancer‐induced bone metastasis
by: Kunihisa Nezu, et al.
Published: (2019-11-01)

Serum Dickkopf-1 as a potential prognostic marker in patients with rheumatoid arthritis
by: Dina A. Ali, et al.
Published: (2021-12-01)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
by: Radosław Słopień, et al.
Published: (2017-10-01)

VASCULAR CALCIFICATION, ATHEROSCLEROSIS AND BONE LOSS (OSTEOPOROSIS): NEW PATHOPHYSIOLOGICAL MECHANISMS AND FUTURE PERSPECTIVES FOR PHARMACOLOGICAL THERAPY
by: A. Dolzhenko, et al.
Published: (2016-12-01)

Evaluation of the effect of metformin treatment on markers of bone formation and resorption in patients newly diagnosed with Type 2 diabetes
by: Zuhal Karaca Karagoz, et al.
Published: (2022-12-01)

Correction: Efficacy of Denosumab in the Treatment of Postmenopausal Osteoporosis: One-year Follow-up, Single Center Study
by: İsmail Tunçekin, et al.
Published: (2023-12-01)

Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice
by: I A Skripnikova, et al.
Published: (2017-12-01)

Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis
by: Jia Peng, et al.
Published: (2021-05-01)

Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis
by: Swati Rajput, et al.
Published: (2023-02-01)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
by: Ishikawa K, et al.
Published: (2016-12-01)

LRP6 High Bone Mass Characterized in Two Generations Harboring a Unique Mutation of Low‐Density Lipoprotein Receptor‐Related Protein 6
by: Michael P Whyte, et al.
Published: (2023-04-01)

Research progress in the regulation of bone homeostasis by long noncoding RNAs
by: FAN Lin-yuan, LI Hong-ling
Published: (2020-01-01)

Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study
by: Nihal Tezel, et al.
Published: (2021-12-01)

Multiple idiopathic external cervical root resorption in patient treated continuously with denosumab: a case report
by: Katarína Mikušková, et al.
Published: (2022-04-01)

Hypothesis: Coupling between resorption and formation in cancellous bone remodeling is a mechanically controlled event
by: Reinhold Gottfried Erben
Published: (2015-05-01)

Long-term consequences of osteoporosis therapy with denosumab
by: Francisco Bandeira, et al.
Published: (2022-12-01)

Serum Sclerostin Level Is Negatively Associated with Bone Mineral Density in Hemodialysis Patients
by: Jing-Wun Lu, et al.
Published: (2022-03-01)

Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
by: Vladimir Gerov, et al.
Published: (2023-07-01)

Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy
by: Stepan Kutilek
Published: (2017-12-01)

Assessment of the Therapeutic Potential of Melatonin for the Treatment of Osteoporosis Through a Narrative Review of Its Signaling and Preclinical and Clinical Studies
by: Yongchao Zhao, et al.
Published: (2022-05-01)

Published: (2022-02-01)

Chronic Iron Deficiency as an Emerging Risk Factor for Osteoporosis: A Hypothesis
by: Laura Toxqui, et al.
Published: (2015-04-01)